Probiotix Health PLC
F:X90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Probiotix Health PLC
Cash & Cash Equivalents
Probiotix Health PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Probiotix Health PLC
F:X90
|
Cash & Cash Equivalents
£1.6m
|
CAGR 3-Years
124%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash & Cash Equivalents
£467.7m
|
CAGR 3-Years
12%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Cash & Cash Equivalents
$149.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash & Cash Equivalents
£43.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Cash & Cash Equivalents
£96.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
26%
|
|
|
Niox Group PLC
LSE:NIOX
|
Cash & Cash Equivalents
£19.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
22%
|
CAGR 10-Years
-19%
|
|
Probiotix Health PLC
Glance View
ProBiotix Health Plc develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. The company is headquartered in York, North Yorkshire and currently employs 2 full-time employees. The company went IPO on 2022-03-31. The firm develops probiotics to tackle cardiovascular disease and other lifestyle conditions. The company manufactures cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (LP-LDL). ProBiotix commercializes LP-LDL as an ingredient and in a range of white and own-label products under its CholBiome range. The CholBiome portfolio consists of four products, namely CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH. LP-LDL helps to improve blood lipid profiles and blood pressure. The firm's development pipeline is fuelled by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact human physiology and bring potential health benefits. These platforms are applicable across a range of other human diseases. The firm is focused on identifying and developing microbial strains, compounds, and formulations for use in the nutraceutical industry.
See Also
What is Probiotix Health PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.6m
GBP
Based on the financial report for Dec 31, 2024, Probiotix Health PLC's Cash & Cash Equivalents amounts to 1.6m GBP.
What is Probiotix Health PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
56%
Over the last year, the Cash & Cash Equivalents growth was 10%. The average annual Cash & Cash Equivalents growth rates for Probiotix Health PLC have been 124% over the past three years , 56% over the past five years .
